Immunization

Combined Therapeutics CEO, Romain Micol, to Present at the World Vaccine Congress Europe 2023

Retrieved on: 
Wednesday, October 11, 2023
Congress, UTR, CTX, RNA, Cell, Immunity, Therapy, Liver, MicroRNA, MPH, Heart, Safety, Biotechnology, CEST, Combined, Immunization, Tissue, Messenger, NHP, Pharmaceutical industry, Vaccine

BOSTON, Oct. 11, 2023 /PRNewswire/ -- Combined Therapeutics Inc. (CTx), a privately held biotechnology company developing the next generation of mRNA vaccines and therapeutics with a novel modified-mRNA platform to treat and prevent infectious diseases and cancer, today announced the participation of Romain Micol, M.D., MPH, Ph.D., President and CEO of Combined Therapeutics, as a speaker at the World Vaccine Congress Europe 2023, taking place from October 17 to 19 in Barcelona, Spain.

Key Points: 
  • "We are elated to share our findings at the World Vaccine Congress Europe 2023 and to discuss our progress toward developing the next generation of mRNA vaccines," said Dr. Romain Micol, CEO of Combined Therapeutics.
  • "Our MOPCTx mRNA platform has demonstrated exceptional promise in preclinical studies, showcasing an enhanced biodistribution profile, improved organ protection, and no compromise in vaccine efficacy.
  • Its precision in targeting therapeutic protein expression while simultaneously safeguarding vital organs represents an important advancement in our field."
  • Proof of concept studies in non-human primates (NHPs) confirmed the efficacy of the MOPCTx platform in decreasing overall systemic vaccine antigen expression after intramuscular immunization.

New Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

Retrieved on: 
Wednesday, October 11, 2023
Incidence, Health, COVID-19, Public, ASX, CSL, Outcome, Death, Season, Influenza, Vaccination, Person, Immunization, ICU, Vaccine

The data highlights the effectiveness and value of influenza vaccination in the U.S. across all relevant age groups, risk profiles, and influenza seasons with different levels of influenza burden.1,2,3 These analyses will be presented during poster sessions this week at the IDWeek 2023 conference taking place in Boston, Mass.

Key Points: 
  • The data highlights the effectiveness and value of influenza vaccination in the U.S. across all relevant age groups, risk profiles, and influenza seasons with different levels of influenza burden.1,2,3 These analyses will be presented during poster sessions this week at the IDWeek 2023 conference taking place in Boston, Mass.
  • from October 11-15, 2023.
  • "Observing an ever-growing set of real-world outcomes is critical to ensuring that cell-based influenza vaccine technology continues to push public health forward."
  • "With the 2023/24 Northern Hemisphere influenza season underway, we're committed to working with our partners in public health to help demonstrate the importance of vaccination for our communities and health systems, particularly following a significant drop in flu immunization rates since the COVID-19 pandemic."

ApiJect Systems, Corp. Bolsters Global Health Team with Esteemed Anthropologist and Leading Expert on Vaccine Hesitancy, Dr. Heidi J. Larson, as Senior Advisor

Retrieved on: 
Wednesday, October 4, 2023
Communication, Risk, Stuck: How Vaccine Rumors Start and Why They Don't Go Away, University, Institute for Health Metrics and Evaluation, BBC, Health education, University of Washington, World Health Organization's response to the COVID-19 pandemic, COVID-19, Senior advisor, ApiJect Systems, Research, Vaccine hesitancy, Doctor of Philosophy, Theory, UNICEF, Thought, Vaccine Confidence Project, Patient, Evaluation, Platform, Tropical medicine, Global North and Global South, Hygiene, Health, Immunization, Woman, Clinical, London School of Hygiene and Tropical Medicine, Management, Vaccine, Anthropology

Dr. Larson is best known for groundbreaking research that advances the medical, scientific, social, and political understanding of vaccine hesitancy.

Key Points: 
  • Dr. Larson is best known for groundbreaking research that advances the medical, scientific, social, and political understanding of vaccine hesitancy.
  • She has engaged in effective advocacy for better health education and policies by building consensus and critical partnerships that influence health interventions and shape policies.
  • She is the Founder and Director of The Vaccine Confidence Project, which since 2010 has worked throughout the world to overcome vaccine hesitancy.
  • She has published extensively on the topic, including her book, STUCK: How Vaccine Rumors Start—and Why They Don't Go Away.

Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Pharmaceutical, Teens, Health, Children, Infectious Diseases, Consumer, Clinical Trials, Vaccine, Immunization, Communication, VE, SAGE, Dengue fever, Hospital, Public, Feedback, TAK, Infection, Overalls, Fever, Person, Incidence, Fever Dream, Risk, VCD, Ageing, WHO, Safety, Disease, Takeda

Takeda ( TSE:4502/NYSE:TAK ) today announced that the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization shared recommendations for use of QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003).

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization shared recommendations for use of QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003).
  • SAGE made the following recommendations:
    The vaccine to be considered for introduction in settings with high dengue disease burden and high transmission intensity to maximize the public health impact and minimize any potential risk in seronegative persons.
  • The vaccine to be introduced to children aged 6 to 16 years of age.
  • Within this age range, the vaccine should be introduced about 1-2 years prior to the age-specific peak incidence of dengue-related hospitalizations.

How to Make a Difference This Halloween

Retrieved on: 
Monday, October 2, 2023
Diamond, Education, Survival, UNICEF, Movement, Candy, Halloween, Sanitation, Child, UNICEF USA, Microsoft family features, Horn, Immunization, Social media, Entertainment

This year, you can make Halloween more than just a festive holiday by making a difference for children worldwide.

Key Points: 
  • This year, you can make Halloween more than just a festive holiday by making a difference for children worldwide.
  • Donations to the Trick-or-Treat for UNICEF campaign raise critical funds and relief for children where and when they need it most.
  • "Trick-or-Treat for UNICEF is a beloved Halloween tradition celebrated over the last 73 years by families all across America, mine included," said Shelley Diamond, chief marketing officer at UNICEF USA.
  • "This year, we thought outside the renowned, 'little orange box' and are thrilled to introduce the 'click-or-treat' virtual experience.

FMWC HPV Task Force Issues New White Paper to Address Ongoing HPV Vaccination Crisis in Ontario

Retrieved on: 
Sunday, October 1, 2023
Vaccine, Communication, Public Health Ontario, Vaccination, Accidental Death and Disability: The Neglected Disease of Modern Society, White paper, Public, Parent, COVID-19, Head, Medical Women's Federation, Research, Neck, Government, School, Dentist, Student, Pharmacist, Federation, Anal cancer, Patient, Cervical cancer, Physician, Risk, FMWC, Disability-adjusted life year, Fire Prevention Week, HPV, Immunization

The White Paper offers 10 essential recommendations for health care providers, Public Health Ontario and the Ontario Ministry of Health aimed at recovering pre-pandemic school-led immunization levels in the province and addressing the barriers to reaching Canada's 90 percent HPV immunization coverage commitment.

Key Points: 
  • The White Paper offers 10 essential recommendations for health care providers, Public Health Ontario and the Ontario Ministry of Health aimed at recovering pre-pandemic school-led immunization levels in the province and addressing the barriers to reaching Canada's 90 percent HPV immunization coverage commitment.
  • The White Paper produced by the task force calls on the provincial government to immediately work towards implementing a unified provincial vaccine registry as a primary goal.
  • All together, the 10 essential recommendations outlined in the White Paper aim to increase HPV vaccine awareness among key groups and improve deficiencies in communication, collaboration, technology and access.
  • For more details on the FMWC White Paper and its recommendations, please visit canadavshpv.ca .

Medicat and TrackMy Forge Partnership to Streamline Immunization Compliance

Retrieved on: 
Thursday, September 28, 2023
Partnership, Student, Education, University, Record, Time-saving bias, School, Health, Immunization, Headache, Vaccine, Tutoring, Audit

ATLANTA, Sept. 28, 2023 /PRNewswire/ -- Medicat, the #1 provider of electronic health records software in college health, is thrilled to announce an exciting partnership with TrackMy , a leader in immunization compliance solutions.

Key Points: 
  • ATLANTA, Sept. 28, 2023 /PRNewswire/ -- Medicat, the #1 provider of electronic health records software in college health, is thrilled to announce an exciting partnership with TrackMy , a leader in immunization compliance solutions.
  • This verification engine streamlines immunization compliance by allowing students to retrieve their immunization records through TrackMy's nationwide clinical network as part of care coordination.
  • Key benefits of this partnership include:
    Streamlined Compliance: The integration between Medicat and VeriVax eliminates much of the manual review of immunization records, ensuring records are more accurate and up to date.
  • To learn more about this partnership and how your campus can streamline immunization compliance, please visit our website .

Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration

Retrieved on: 
Thursday, September 28, 2023
Therapy, Senior, G protein-coupled receptor, SARS-CoV-2, Antibody, CHI, Protein, DOT, KCNA3, Immunization, SEMA4D, Eurosport 1, Safety, Vaccine, Hook effect, Research

ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s and other neurodegenerative diseases through the inhibition of SEMA4D, announces a new publication in the journal mAbs describing a novel way in which its proprietary ActivMAb® poxvirus platform can enable the presentation of high complexity, hard-to-drug proteins as targets for antibody discovery.

Key Points: 
  • This allows a consistent supply of protein to be readily available as antibody immunogens and greatly facilitates the screening, selection and affinity improvement of antibody candidates.
  • “We believe this new “Antigen Virus” application is a powerful complement to Vaccinex’ ActivMAb platform and we are pleased for this work to be published in mAbs.
  • This novel application of Vaccinex’s ActivMAb technology was successfully used with OmniAb, Inc.’s high-throughput B cell screening and proprietary in vivo immunization platform.
  • OmniAb was able to select antibodies against challenging multipass membrane targets (ion channel Kv1.3 and a chemokine receptor), that were displayed on ActivMAb antigen viruses.

GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference

Retrieved on: 
Wednesday, September 20, 2023
Omicron, Animal, GeoVax, Face, SARS-CoV-2, Biotechnology, COVID-19, Georgia State University, Infection, Inflammation, Antibody, Protein, Protein structure, GEO, Dihydrolipoyllysine-residue (2-methylpropanoyl)transferase, Immune system, Cancer, Corona Labs Inc., Immunization, Death, MVA, Vaccine

ATLANTA, GA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of preclinical vaccine efficacy data for GEO-CM02, a multi-antigen SARS-CoV-2 vaccine. The new unpublished data were presented during the Keystone Symposia on Molecular and Cellular Biology, Vaccinology During and After COVID-19, being held in Atlanta, Georgia on September 17-20, 2023.

Key Points: 
  • The new unpublished data were presented during the Keystone Symposia on Molecular and Cellular Biology, Vaccinology During and After COVID-19, being held in Atlanta, Georgia on September 17-20, 2023.
  • However, vaccine efficacy is disrupted by emerging variants that contribute to neutralizing antibody evasion, requiring updating and booster doses.
  • Together, these data indicate that immunization with the multi-antigen GEO-CM02 vaccine can protect against severe disease and death induced by SARS-CoV-2 infection and regardless of the variant.
  • The multi-antigen, MVA-vectored vaccine design is currently being evaluated by GeoVax in three Phase 2 clinical trials using a similar vaccine (GEO-CM04S1).”

Global Impact, on Behalf of the Advancing Health Online Initiative (AHO), Announces Collaboration with Gavi, the Vaccine Alliance at the Concordia Annual Summit

Retrieved on: 
Tuesday, September 19, 2023
Online, MSD, Learning, NJ, Private sector, General assembly, United Nations, Meta, Vaccination, Public, Policy, COVID-19, AHO, Global health, United Nations General Assembly, Research, Global Impact, Vaccine hesitancy, Organization, SBC, Gavi, Merck, Social, Merck & Co., Health, Immunization, Social media, Pharmaceutical industry, Marketing

AHO’s goal is to support effective integration of social media as a core component of social behavior change (SBC) to improve health outcomes.

Key Points: 
  • AHO’s goal is to support effective integration of social media as a core component of social behavior change (SBC) to improve health outcomes.
  • To achieve this, AHO collaborates with organizations working at the intersection of technology, global health, and SBC.
  • Vaccine hesitancy long precedes the lack of confidence witnessed globally during the COVID-19 pandemic and may stem from distrust in the vaccine provider and medical system.
  • VaxSocial will launch a call for proposals in several Gavi-supported countries including India, Nigeria, and Indonesia.